The COMBAT trial showed that a CXCR4 antagonist combined with PD-1 inhibitors and chemotherapy could improve disease control and prolong survival in pancreatic cancer, mainly through increased CD8+ cell infiltration and reduced myeloid-derived suppressor cells, suggesting that CXCR4 inhibitors combined with traditional therapies can improve prognosis for tumor patients (78, 79) (Supplementary Table S1). The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.